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Rationale: Patients hospitalized for a COPD exacerbation are usually of advanced age, with
functional deterioration, and suffering an increased number of associated conditions, but little
is known about gender differences. Our hypothesis is that the frequency and type of comorbid-
ities differ in male and female COPD patients.
Material and methods: A cross-sectional, multicentre study of patients hospitalized for a COPD
exacerbation. All of them had COPD confirmed by baseline forced spirometry with a broncho-
dilator test. Comorbidity information was collected using the Charlson index, and an ad hoc
questionnaire that included other common conditions not included in the Charlson index.
Results: We studied 398 patients, 353 men (89%) and 45 women (11%), with a mean (S.D.) age of
73.7 (8.9) years and a percent predicted FEV1 of 43.2 (12.5). The mean score of the Charlson
index was 2.7 (2.0), with no differences by gender; in contrast, the mean number of all comorbid
conditions assessed was 3.7 (1.7) in men and 1.8 (1.8) in women (p < 0.05). Overall, 55% of the
patients had arterial hypertension, 26% diabetes mellitus, 27% chronic heart failure, and 17%
ischemic heart disease. Female COPD patients had a lower prevalence of ischemic heart disease
(pZ 0.008) and alcoholism (pZ 0.03), but presented more frequently with chronic heart failure
(pZ 0.03), osteoporosis (pZ 0.007) and diabetes mellitus without complications (pZ 0.02).icine Service, Hospital Mu´tua de Terrassa. Plaza Dr. Robert 5, 08221 Terrassa, Barcelona, Spain. Tel.:
b.es, palmagro@mutuaterrassa.es (P. Almagro).
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254 P. Almagro et al.Conclusions: Comorbidities are common in patients hospitalized for a COPD exacerbation, but
their relative distribution varies by gender. The exclusive use of the Charlson index underesti-
mates comorbidities in COPD patients.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) affects more
than 10% of the adult population worldwide, and the
associated mortality is expected to increase and become
the third leading cause of death by the year 2030.1,2 An
ever-increasing number of these deaths will be among
women, and already in some parts of the world, female
mortality exceeds that for men.3,4 Additionally, the Global
Initiative for Obstructive Lung Disease (GOLD) guidelines
consider COPD as a preventable and treatable condition,
with an extrapulmonary component that contributes to
patient prognosis.5 This extrapulmonary component refers
both to the systemic effects of COPD (weight loss, myop-
athy, and others) and to the frequently occurring comor-
bidities (ischemic heart disease, cancer, osteoporosis, and
others). Added to respiratory failure in severe COPD
patients, also ischemic heart disease and cancer are
frequent causes of death in these patients.6,7
In spite of the importance of comorbidities in COPD, it is
only recently that their role has been comprehensibly
examined in review papers8,9 or in clinical management
guidelines.5,10 There continue to be few data on the
differences in COPD comorbidities associated with
gender.11,12 To date, most studies have used the Charlson
index for the assessment of comorbidities; this index was
initially developed for administrative use in hospital regis-
tries.13 However, the Charlson index, which has been shown
to be a good predictor of prognosis in COPD,14 fails to show
information on conditions that are not included within it,
but which in some cases might be more frequent among
women with COPD, thereby producing an underestimation
of comorbidity among them.11,15,16 The present study was
designed to describe the comorbidity associated with COPD
among patients hospitalized for a COPD exacerbation,
taking into account both the comorbidities included in the
Charlson index as well as others, with the aim of deter-
mining whether there are differences in the distribution of
comorbidities in male and female COPD patients.Material and methods
ECCO (Estudio de Comorbilidad en pacientes EPOC hospi-
talizados en Servicios de Medicina Interna), acronym in
Spanish for ‘‘A comorbidity study in COPD patients hospi-
talized in internal medicine departments in Spain’’, is an
observational, prospective multicenter study, participated
in by 26 hospital centers throughout Spain17 (seeAppendix).
The ECCO study included those patients admitted with
a COPD exacerbation to any of the participating internal
medicine departments consecutively between January 1,
2007, and December 31, 2008. They were all confirmed at
stable condition to fulfill the COPD diagnostic criteria ofpulmonary function test (FEV1 < 80% of the predicted value
and FEV1/FVC <0.7 following administration of a broncho-
dilator).5,10 Therefore, they were all GOLD stage II or
more,5 which is severity moderate or higher.10
Upon admission, all patients were evaluated with
a standardized questionnaire, and their clinical and func-
tional data were recorded. Data registered included the
identifying data in the registry of the index hospital-
izationdage, gender, and reason for hospitalization, and
forced spirometry in stable condition before and after of
a bronchodilator test. Additionally, smoking history, total
number of admissions for COPD (or other causes) in the
previous year, and the total number of COPD exacerbations
in the 12 months prior to the index hospitalization were
recorded. We used the Anthonisen criteria18 to define
exacerbation and to evaluate possible infectious etiology.
For the assessment of associated comorbidities we used
all those in the Charlson index,14 as well as another series
of non-Charlson conditions which we considered to be
relevant: osteoporosis, anemia, arterial hypertension,
alcoholism, oedemas, thrombo-embolic disease, and
arrhythmia among others.
Weobtained fromall patients a series of obligatory clinical
and biological parameters (temperature, arterial pressure,
cardiac frequency, height, weight, BMI, dyspnea as per the
modified Medical Research Council (mMRC) baseline gas-
ometry at admission, hematocrit, hemoglobin, and baseline
glycemia values, and other non-obligatory parameters such
as the presence or absence of cardiac sinus rhythm and
echocardiography, whenever clinically indicated.
Finally, we registered data referring to the index hospi-
talization, including main and secondary diagnosis at
discharge, length of stay, and venue of subsequent follow-up.
The study was approved by the Clinical Investigation
Ethics Committee of the coordinating center and all of
those participating contributed data voluntarily and signed
an informed, written consent form.
Data analysis
Univariate, descriptive analysis of all study variables was
conducted. Qualitative variables were expressed as abso-
lute frequencies and percentages, while quantitative vari-
ables were summarized as mean and standard deviation.
The comparison among means was made using the Student t
test for independent samples. The ManneWhitney U test
was used for not normally distributed variables. Chi2 test or
the Fisher exact test were used for the comparison of
proportions. The association between quantitative vari-
ables was studied with the Pearson correlation coefficient,
or the Spearman rho coefficient, according to the normality
of data. In all analyses, a bilateral hypothesis with a p value
less than 0.05 to identify differences was considered
significant.
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Initially, data from 503 COPD hospitalizations were
collected, of which 6 were immediately eliminated as
duplicates. Of the 497 remaining cases, 99 were excluded
because of failure to fulfill all inclusion criteria (27 patients
were admitted for causes other than an exacerbation of
COPD, and 72 failed to meet the baseline spirometric
criteria). These 99 patients excluded were no different
from the included patients in terms of their age and gender
distribution (data not shown).
Overall, the study was carried out in 398 patients, 353 of
them men (89%) and 45 women (11%). The mean age was
73.7 years (8.9). The principal demographic and clinical
characteristics of the study population are shown in
Table 1, stratified by gender. It can be seen that there were
no differences for most comparisons by gender, although
women had a larger proportion of non-smokers and had
a larger mean percent predicted FEV1, less use of chronic
oxygen therapy, and less severe gasometry valuesTable 1 Baseline sociodemographic and clinical characteristics
Variable Men N Z
Age, mean (SD) 73.9 (8.8
Age groups, n (%)
<60 years 24 (6.8
60e70 years 68 (19
70e80 years 165 (46
>80 years 96 (27
Smoking, n (%)
Smoker 60 (17
Ex-smoker 279 (79
Non-smoker 14 (4%
Packs/year, mean (SD)a 49.2 (31
BMI, mean (SD) 26.9 (5.2
FEV1 in L., mean (SD) 1.26 (0.5
Percent predicted FEV1, mean (SD) 42.7 (12
FEV1/FVC, mean (SD) 0.52 (0.1
GOLD stage, n (%)
Moderate 111 (31
Severe 192 (54
Very severe 50 (14
mMRC dyspnea, mean (SD) 3.7 (0.9
Home oxygen therapy before admission, n (%) 135 (38
Gasometry on admission
pH, m (SD) 7.4 (4.9
paCO2, m (SD) 45.6 (10
paO2, m (SD) 56.9 (11
Hospitalizations for COPD in the previous 12 months,
mean (SD)
3.3 (3.2
Anthonisen criteria
- Increased dyspnea, n (%)
- Increased phlegm, n (%)
- Change in sputum color, n (%)
328 (92
270 (7
353 (6
Infection as likely cause of the exacerbation, n (%) 277 (78
a excluding non-smokers.(p < 0.05). Our female COPD participants who were never-
smokers were significantly older than those that had
a history of tobacco use (67.1 (0.7) vs 76.3 (7.9):
p Z 0.002), although with no differences in FEV1 or
comorbidity distribution.
The mean percent predicted FEV1 was 43.2% (12.5) and
this correlated well with previous hospitalizations for COPD
and the mMRC dyspnea scale (p < 0.001). A total of 356
patients (90%) had required at least one hospital hospi-
talization for any cause in the previous year, with an
average of 5.0 (3.9) hospitalizations for those patients with
at least one. There were no differences by gender, with
a mean of 5.1 (3.9) hospitalizations in men and 4.9 (3.4) in
women. Regarding a history of prior hospitalization for
exacerbations of COPD, 336 patients (84%) had been
hospitalized in the previous year, with a mean number of
3.2 (3); again no differences were found by gender (3.3
vs. 2.5, p > 0.05).
The average length of stay observed was 9.8 day (6.5);
this was somewhat lower in women than men [8.0 (3.0) vs.of the 398 participants, by gender.
353 (89%) Women N Z 45 (11%) Total P
) 72.8 (9.3) 73.7 (8.9) 0.4
0.76
%) 5 (11.1%) 29 (7.3%)
.3%) 8 (17.8%) 76(19.1%)
.7%) 21 (46.7%) 186 (46.7%)
.2%) 11 (24.4%) 107 (26.9%)
0.001
%) 8 (17.8%) 68 (17.1%)
%) 9 (20%) 288 (72.4%)
) 28 (62.2%) 42 (10.6%)
.9) 42.8 (33) 57.2 (27.3) 0.39
) 26.9 (5) 27 (5.2) 0.9
) 0.99 (0.3) 1.23 (0.44) 0.009
.6) 46.6 (11.4) 43.2 (12.5) 0.048
) 0.54 (0.14) 0.52 (0.16) 0.2
0.08
.4%) 21 (46.7%) 132 (33.2%)
.4%) 21 (46.7%) 213 (55.5%)
.2%) 3 (6.7%) 53 (13.3%)
) 3.6 (1) 3.7 0.8
.2%) 11 (24.4%) 146 (37%) 0.05
) 7.39 (6.6) 7.40 (5.15) 0.06
.5) 46.3 (9.6) 45.7 (10.4) 0.6
.2) 60.9 (12.7) 57.4 (11.4) 0.03
) 2.5 (2.2) 3.2 0.1
.9%) 41 (91.1%) 369 (92.7%) 0.4
6.5%) 33 (73.3%) 303 (76.1%) 0.4
3.2%) 25 (55.6%) 248 (62.3%) 0.2
.5%) 35 (77.8%) 312 (78.4%) 0.7
00,05
0,1
0,15
0,2
0,25
0,3
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Charlson index
%
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p = 0.954
Figure 1 Distribution of Charlson-included comorbidities, by
gender.
256 P. Almagro et al.10.0 (6.8)], but again not reaching statistical significance
(pZ 0.61). As expected, length of stay was longer for those
patients with lower FEV1 values (p < 0.001) and for those
with worse scores on the dyspnea scale (p< 0.001), although
we did not find a relationship between length of stay and
comorbidity measured numerically (p Z 0.8) or with Charl-
son index (p Z 0.6). A total of 369 patients (93%) reported
increased dyspnea on admission, 303 (76%) an increase in
phlegm, and 248 (62%) a change in sputum color. The
attending physicians considered the cause of the exacerba-
tion to be infectious in 337 cases (85%). The mortality
observed during hospitalization was 5% (21 patients) and this
was related with FEV1 [35.6 (10.2) vs. 43.6 (12.5); p< 0.005],
but not with age, gender, comorbidity or number of previous
hospitalizations (p > 0.05).
At discharge, patients were recommended to continue
controls with primary care (34%), pneumology (32%) or
internal medicine (34%), with no differences by gender
(data not shown).
The most frequent comorbid conditions observed were
arterial hypertension (55%), anemia (33%), arrhythmias
(27%), diabetes without complications (26%), chronic heart
failure (27%), ischemic cardiopathy (17%), and a history of
myocardial infarction (9%). Fourteen percent suffered
active alcoholism. The number of chronic conditions wasTable 2 Frequencies of comorbidities, by gender.
Comorbidity Men N Z 353 (89%)
Myocardial infarction 32 (9.1%)
Ischemic Heart disease 66 (18.7%)
Chronic heart failure 89 (25.2%)
Peripheral vascular disease 48 (13.6%)
Cerebrovascular disease 31 (8.8%)
Dementia 13 (3.7%)
Connective tissue disease 6 (1.5%)
Peptic ulcer 46 (13%)
Mild liver disease 28 (8%)
Diabetes without complications 85 (24%)
Diabetes with organ damage 12 (3.4%)
Hemiplegia 3 (1%)
Moderate kidney failure 24 (6.8%)
Solid tumor without metastasis 24 (6.8%)
Leukemia 6 (1.7%)
Lymphoma 2 (0.6%)
Moderate or serious liver disease 9 (2.5%)
Solid tumor with metastasis 6 (1.7%)
AIDS 1 (0.3%)
Charlson index, average (DE) 2.8 (1.7)
Other (non-Charlson)
Osteoporosis 27 (7.6%)
Anemia 120 (34%)
Arterial hypertension 187 (53%)
Alcoholism 55 (15,6%)
Oedemas 107 (30%)
Thrombo-embolic disease 13 (3.7%)
Arrhythmia 92 (26%)
Total comorbidities,
average (DE)
3.7 (1.7)3.6 (1, 8), while the mean score on the Charlson index was
2.72 (2). We found no significant differences between
comorbidity measured with the Charlson index and gender
[2.8 (1.7) in men vs. 2.6 (1.2) in women], but there were
significant differences overall in associated conditions [3.7
(1.7) in men vs. 1.8 (1.8) in women; p Z 0.05]. Female
COPD patients had a lower prevalence of ischemic heart
disease and alcoholism, but a higher prevalence of heartWomen N Z 45 (11%) Total p
2 (4.4%) 34 (9%) 0.2
2 (4.4%) 68 (17%) 0.008
18 (40%) 107 (27%) 0.03
2 (4.4%) 50 (13%) 0.06
7 (15.6%) 38 (10%) 0.1
2 (4.4%) 15 (4.4%) 0.5
1 (0.3%) 7 (2%) 0.6
3 (6.7%) 49 (12%) 0.16
1 (2.2%) 29 (7.3%) 0.13
18 (40%) 103 (26%) 0.02
2 (4.4%) 14 (3.5%)4 0.48
2 (2.2%) 4 (1%) 0.38
2 (4.4%) 26 (6.5%) 0.4
2 (4.4%) 26 (6.5%) 0.4
0 (0%) 6 (1.5%) 0.5
0 (0%) 2(0.5%) 0.8
0 (0%) 9(2.3%) 0.3
1 (2.2%) 71(8%) 0.6
0 (0%) 1 (0.3%) 0.9
2.6 (1.2) 2.7 (2.0) 0.6
10 (22%) 37 (9.7%) 0.004
13 (29%) 265 (33%) 0.3
31 (70%) 218 (55%) 0.03
1 (2.2%) 56 (14%) 0.007
25 (56%) 132 (33%) 0.01
0 (0%) 13 (3%) 0.2
16 (36%) 108 (27%) 0.1
1.8 (1.8) 3.6 (1.8) 0.4
Other comorbidities
Chi
2
p = 0.061
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0
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Figure 2 Distribution of all evaluated comorbidities, by
gender.
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tion of comorbidities according to the Charlson index by
gender is presented in Figure 1, which clearly shows no
differences (p Z 0.954). However, the distribution of all
comorbidities assessed was of borderline non-significance
(p Z 0.061), as presented in Figure 2. Finally, Figure 3
details the specific comorbidities showing significant
differences by gender, namely oedemas, chronic heart
failure, arterial hypertension, and osteoporosis, which
were more frequent in women, while ischemic heart
disease, and alcoholism were more frequent in men
(P < 0.05).
When analyzing correlations, the number of all comor-
bidities assessed, expressed numerically, was associated
with the number of hospitalizations for any cause during the
previous year (p < 0.001) and dyspnea scale (p < 0.001). In
a similar analysis, the Charlson indexwas associatedwith the
number of hospitalizations for any cause during the previous
year, but not with the dyspnea scale.Discussion
Our study concludes there is a different distribution of
comorbidities in male and female COPD patients, and it
confirms the high prevalence of these associated conditions
in any patients hospitalized for a COPD exacerbation; it also0
10
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80
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P<0.007 P<0.04
%
P<0.001
P<0.001
P<0.03
P<0.03
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Figure 3 Distribution of selected comorbidities, by gender.highlights the underestimation of some important comor-
bidities if we use the Charlson index only.19e22
In contrast to the case for men, there are few comor-
bidity studies in women with COPD; in one case-control
study adjusted for FEV1 carried out among ambulatory COPD
patients, women had fewer comorbid illnesses than men
(2 vs. 4; p < 0.05).11 Two limitations of this study can be
identified: comorbidities were determined exclusively with
the Charlson index, and women were on average eight years
younger than men.11 Au contraire, Sidney et al. in another
study carried out in an ambulatory setting, reported that
women with COPD were at a greater risk of requiring
hospitalization during the follow-up for a myocardial
infarction, stroke, or other cardiovascular diseases.23
The presence of comorbidities is much greater in the
hospitalized population. In our COPD patients the mean
number of comorbidities was 3.6 conditions, while the
point value on the Charlson index was 2.7. Some 55% of the
patients suffered arterial hypertension, 26% diabetes mel-
litus, 27% heart failure, and 17% ischemic heart disease.
COPD women had less prevalence of ischemic heart disease
and alcoholism, but greater heart failure, osteoporosis and
diabetes. These figures are clearly greater than those
reported by Holguin et al. in a study based on hospital
discharge coding.24 The prevalence of heart failure in our
study (30%) is similar to that described in ambulatory
patients with severe COPD who are assessed by echocar-
diography,25 and it is greater among women (40%) than
among men (25%).
Of interest, 9% of our patients had a history of previous
myocardial infarction. This association may be explained in
part by smoking as a common risk factor, with the inflam-
matory component of both conditions acting via multiple
mechanisms. Sin et al. concluded a relationship between
the CRP levels in patients with COPD and a greater number
of forthcoming cardiovascular events.26
It is now recognized that mortality in COPD patients is
often attributable to the associated conditions. Thus, data
derived from the TORCH trial with more than 6000 patients
show that cause-specific mortality at three years was linked
to pulmonary causes in 35% of cases, cardiovascular causes
in 27%, and cancer in 21%.6 In a recent report with an
extended follow-up of participants in the ISOLDE trial,
similar data were obtained, but as baseline severity was
higher, the relative mortality for respiratory causes was
increased among patients dying at an older age.27 It can be
hypothesized that COPD patients who die from respiratory
causes are those who did not die earlier from cardiovas-
cular causes or cancer. Accordingly, mortality due to
respiratory causes predominates in severe or very severe
COPD patients, in whom the 5-year mortality is as high as
46%.28,29 All these observations are largely in male COPD
patients, and there are no data available on these trends in
COPD women.
There are a number of limitations of our study to discuss.
A major limitation is the low proportion of women (11%)
among those hospitalized with COPD in our setting and
studied here. This might partly be explained by some
underdiagnosis of COPD in women, as described else-
where,30 but more likely it is related to the secular trends
of smoking in Spain, with women massively exposed to
active smoking after the 1950s only. Nowadays, however,
258 P. Almagro et al.Spain ranks high among the countries with the greatest
prevalence of female smoking31; it is therefore expected
that the female COPD burden, and in this case hospitali-
zations and mortality, will significantly increase in the
coming years in Spain. At any rate, the 9/1 male/female
ratio in our study is similar to that found in other clinical
and epidemiological studies conducted in our setting.32 It is
possible that in other geographical areas with a greater and
longer female smoking history, and therefore with more
women with a more severe COPD distribution, comorbidity
pattern might differ. Replication studies focused on
comorbilidity in COPD by gender in other populations would
be of interest. Given the differences observed in the
number of men and women with COPD included in our
study, an a posteriori calculation was made to determine
the statistical power of the comparison of percentages by
gender for an alpha error of 5%. The results showed suffi-
cient statistical power (80%) to detect a relative risk of 2 or
higher for comparison by gender of variables greater than
5% and lower than 70%, which actually applies to most
comparisons reported here.
In summary, our study confirms the high frequency of
comorbidities among patients hospitalized for a COPD
exacerbation, and their different distribution by gender, and
concludes there is an underestimation of overall comorbid-
ities resulting from the exclusive use of the Charlson index.
Guidelines indicate that appropriate treatment of these
comorbidities, along with the pulmonary disease itself, is
fundamental if we are to improve the management of these
patients, their quality of life, and their prognosis.Acknowledgments
Acknowledgement is made to Esteve Laboratories for their
support in the maintenance of the data base and to Tom
Yohannan for his assistance with the manuscript.
Almagro P. has contributed in the design of the study,
the collection of cases, statistical analysis and the prepa-
ration and submission of the article.
Lo´pez Garcı´a F. has contributed in the design of the
study, the collection of cases and the manuscript review.
Cabrera FJ. has contributed in the design of the study,
the collection of cases and the manuscript review.
Montero L. has contributed in the design of the study,
the collection of cases and the manuscript review.
Morcho´n D has contributed in the design of the study, the
collection of cases and the manuscript review.
Dı´ez J has contributed in the design of the study, the
collection of cases and the manuscript review.
Soriano JB has contributed in statistical analysis and the
preparation and submission of the article.
Appendix
GRUPO EPOC DE LA SOCIEDAD ESPAN˜OLA DE
MEDICINA INTERNA
En nombre de los investigadores del grupo ECCO: Santiago
Mola Caballero de Rodas, Francisco Lo´pez Garcı´a, Jose
Antonio Carratala´ Torregrosa, Gemma Penade´s Cervera,
Juan Custardoy Olavarrieta (Hospital Vega Baja-Orihuela,Alicante); Alberto Muela Molinero, Juan Carlos Borrego
Gala´n, (Hospital General de Leo´n); Rocı´o Llanos Llanos,
Marı´a del Carmen Garcı´a Orenes (Hospital Morales Mese-
guer, Murcia); Juan Manuel Quiroga Iturralde, Gabriel
Zubillaga Garmendia, Elena Zubillaga Azpiroz (Hospital de
Donostia, San Sebastia´n); Mario Ferna´ndez Ruiz (Hospital
General 12 de Octubre, Madrid); Jesu´s Recio Iglesias
(Hospital General Universitario Vall d’Hebron, Barcelona);
Marı´a del Carmen Martı´nez Velasco (Hospital San Juan de
Dios, Pamplona); Marı´a Paz Pe´rez Gutie´rrez (Hospital Clı´n-
ico Universitario, Valladolid); Francisco Javier Cabrera
Aguilar, Pablo Ryan Murua (Hospital General Universitario
Gregorio Maran˜o´n, Madrid), Juan Antonio Oriz Minuesa,
Manuel Montero Pe´rez-Barquero (Hospital General Uni-
versitario Reina Sofı´a, Co´rdoba); Jesu´s Castiella Herrero,
Francisco Jose´ Sanjuan Portugal (Fundacio´n Hospital Cala-
horra, La Rioja); Juan Lucio Ramos Salado, Jose´ Barquero
Romero (Complejo Universitario Infanta Cristina, Badajoz);
Fernando Javier Sa´nchez Lora (Hospital de Antequera,
Ma´laga); Angel Hortal Tavira (Hospital Virgen de Las Nieves,
Granada); Jero´nimo Nieto Lo´pez Guerrero (Hospital de
Cantoblanco, Madrid); Marı´a Cruz Almendros Rivas (Hospital
de Palamos, Madrid); Fernando de la Iglesia Martinez
(Hospital Juan Canalejo, A Corun˜a); Carlos Duen˜as Gutie´r-
rez (Hospital General Yagu¨e, Burgos); Jose´ Luis Lozano Polo
(Hospital General Marque´s de Valdecilla, Santander);
Da´maso Escribano Sevillano (Hospital de Jove, Gijo´n); Luis
Quiroga Prado (Hospital de Leo´n); Carmen Mella Pe´rez
(Hospital Vilagarcia de Arousa, Pontevedra); Ramo´n
Cigu¨enza Gabriel (Hospital Clı´nico San Carlos, Madrid); Jose´
Portillo Sa´nchez (Hospital General de Ciudad Real); Ramon
Boixeda i Viu (Hospital de Mataro´, Barcelona); Lorena
Montero Rivas, Carlos M San Roma´n Tera´n (Hospital
Comarcal Axarquı´a. Ve´lez Ma´laga, Ma´laga); Joan Carles
Trullas Vila (Hospital San Jaume Olot, Gerona); Bernardino
Roca Villanueva (Hospital General de Castello´n); Julio
Montes Santiago (Hospital Do Meixoeiro, Vigo); Jose´ Manuel
Varela (Hospital Virgen del Rocı´o, Sevilla); David Morcho´n,
Juan Carlos Martı´n Escudero (Hospital Universitario Rio
Hortega, Valladolid); Jesu´s Diez Manglano (Hospital Royo
Villanova, Zaragoza); Elena Gu¨ell i Farre´ (Consorci Sanitari
Integral, Barcelona); Olga Arau´jo Loperena (Hospital Xarxa
Tecla, Tarragona); Nuria Galofre´ Alvaro (Hospital de Bada-
lona); Beatriz Sobrino Diaz (Hospital General Universitario
Carlos Haya, Ma´laga); Ana Belen Mecina Gutie´rrez, Marı´a
del Carmen Romero Pe´rez (Hospital de Legane´s, Madrid);
Patricia Crecente Otero, Laura Madrigal Corte´s, Rube´n Dı´ez
Bandera, Vero´nica Alvarez Alamo (Hospital Clı´nico Uni-
versitario, Salamanca); Pedro Almagro Mena (Hospital
Mutua de Terrassa, Barcelona); Pablo Espejo Salamanca
(Fundacio´n Hospital de Manacor, Mallorca); Vicente Giner
Galvan (Hospital de Alcoy, Alicante); Rafael Castillo Rubio
(Hospital La Malvarrosa, Valencia).
References
1. Buist AS, McBurnie MA, Vollmer WM, et al. International vari-
ation in the prevalence of COPD (the BOLD Study): a pop-
ulation-based prevalence study. Lancet 2007;370:741e50.
2. Mathers CD, Loncar D. Projections of global mortality and
burden of disease from 2002 to 2030. PLoS Med 2006;3(11):
e442.
Comorbidity and gender-related differences in patients hospitalized for COPD 2593. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic
Society recommendations formanagement of chronic obstructive
pulmonarydisease e 2007 update. Can Respir J 2007;14:S5e32.
4. Mannino DM, Homa DM, AkinBami LJ, et al. Chronic obstructive
pulmonary disease surveillance-United States, 1971e2000.
MMWR Surveill Summ 2002;51:1e16.
5. Global Strategy for the Diagnosis. Management and Prevention
of COPD, global Initiative for chronic obstructive lung disease
(GOLD) [consulted 29th November 2008]. Available at, http://
www.goldcopd.org; 2008.
6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and flu-
ticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med 2007;356:775e89.
7. Sin DD, Anthonisen NR, Soriano JB, Agustı´ AG. Mortality in
COPD: role of comorbidities. Eur Respir J 2006;28:1245e57.
8. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in
chronic obstructive pulmonary disease. Proc Am Thorac Soc
2008;5:549e55.
9. Rodriguez-Roisin Soriano JB. Chronic obstructive pulmonary
disease with lung cancer and/or cardiovascular disease. Proc
Am Thorac Soc 2008;5:842e7.
10. Celli BR, MacNee W. American Thoracic Society / European
respiratory Society Task Force. Standards for the diagnosis and
treatment of patients with COPD: a summary of the ATS/ERS
position paper. Eur Respir J 2004;23:932e46.
11. de Torres JP, Casanova C, Herna´ndez C, et al. Gender and
COPD in patients attending a pulmonary clinic. Chest 2005;
128:2012e6.
12. de Torres JP, Cote CG, Lo´pez MV, et al. Sex differences in
mortality in patients with COPD. Eur Respir J 2009;33:528e35.
13. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of
a combined comorbidity index. J Clin Epidemiol 1994;47:
1245e51.
14. Almagro P, Calbo E, Ochoa de Echagu¨en A, et al. Mortality after
hospitalization for COPD. Chest 2002;121:1441e8.
15. Torres JP, Casanova C, Montejo de Garcini A, et al. Gender and
respiratory factors associated with dyspnea in chronic
obstructive pulmonary disease. Respir Res 2007;8:18.
16. Carrasco-Garrido P, de Miguel-Dı´ez J, Rejas-Gutierrez J, et al.
Characteristics of chronic obstructive pulmonary disease in
Spain from a gender perspective. BMC Pulm Med 2009;9:2e16.
17. Almagro P, Lo´pez Garcı´a F, Cabrera FJ, et al. Estudio de las
comorbilidades enpacientes hospitalizados por descompensacio´n
de EPOC atendidos en los servicios de Medicina Interna. Estudio
ECCO Rev Clin Esp (in press).
18. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic
therapy in exacerbations of chronic obstructive pulmonary
disease. Ann Intern Med 1987;106:196e204.19. Jørgensen NR, Schwarz P, Holme I, et al. The prevalence of
osteoporosis in patients with chronic obstructive pulmonary
disease: a cross sectional study. Respir Med 2007;101:
177e85.
20. Pinckney RG, O’Brien RO, Piccirillo JF, Littenberg B. Evaluation
of co-morbidity indices in patients admitted for chronic
obstructive pulmonary disease. Monaldi Arch Chest Dis 2004;
61(4):209e12.
21. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic
obstructive pulmonary disease: effect on mortality, hospital
readmission, symptom burden, functional status, and quality
of life. Arch Intern Med 2007;167:60e7.
22. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and
outcomes of diabetes, hypertension, and cardiovascular
disease in chronic obstructive pulmonary disease. Eur Respir J
2008;32:962e9.
23. Sidney S, Sorel M, Quesenberry Jr CP, et al. COPD and incident
cardiovascular disease hospitalizations and mortality: Kaiser
permanente medical Care program. Chest 2005;128:2068e75.
24. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and
mortality in COPD-related hospitalizations in the United
States, 1979 to 2001. Chest 2005;128:2005e11.
25. Render ML, Weinstein AS, Blaustein AS. Left ventricular
dysfunction in deteriorating patients with chronic obstructive
pulmonary disease. Chest 1995;107:162e8.
26. Sin DD, Man SF. Why are patients with chronic obstructive
pulmonary disease at increased risk of cardiovascular diseases?
The potential role of systemic inflammation in chronic
obstructive pulmonary disease. Circulation 2003;107:1514e9.
27. Bale G, Martinez-Camblor Burge PS, Soriano JB. Long-term
mortality follow-up of the ISOLDE participants: causes of death
during 13 years after trial completion. Respir Med 2008;102:
1468e72.
28. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better
predictor of 5-year survival than airway obstruction in patients
with COPD. Chest 2002;121:1434e40.
29. Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status
and mortality in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 1996;153:961e6.
30. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis
of COPD. Chest 2001;119:1691e5.
31. WHO Atlas of smoking worldwide 2003. At www.who.int/
tobacco/statistics/tobacco_atlas/en/. Consulted 3rd March
2009.
32. Garcı´a-Aymerich J, Barreiro E, Farrero E, et al. Patients
hospitalized for COPD have a high prevalence of modifiable risk
factors for exacerbation (EFRAM study). Eur Respir J 2000;16:
1037e42.
